OCUL

OCULAR THERAPEUTIX, INC.

OCUL · CIK 1393434 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$52M
20182025
Net Income−$266M
20182025
Operating CF−$205M
20182025
Free Cash Flow−$217M
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue$0.1B$0.1B$0.1B$0.1B$0.0B$0.0B$0.0B$0.0B
Cost of Revenue$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B—
Gross Profit————————
R&D Expense$0.2B$0.1B$0.1B$0.1B$0.1B$0.0B$0.0B$0.0B
SG&A Expense————————
Operating Income$-0.3B$-0.2B$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B$-0.0B
Net Income$-0.3B$-0.2B$-0.1B$-0.1B$-0.0B$-0.2B$-0.0B$-0.0B
EPS (Basic)$-1.42$-1.22$-1.01$-0.92$-0.09—$-0.53—
EPS (Diluted)$-1.42$-1.22$-1.02$-0.97$-0.98—$-0.53—

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$0.8B$0.5B$0.3B$0.1B$0.2B$0.3B$0.1B$0.1B
Current Assets$0.8B$0.4B$0.2B$0.1B$0.2B$0.2B$0.1B$0.1B
Cash & Equivalents$0.7B$0.4B$0.2B$0.1B$0.2B$0.2B$0.1B$0.1B
Total Liabilities$0.2B$0.1B$0.2B$0.1B$0.1B$0.2B$0.1B$0.0B
Current Liabilities$0.1B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.7B$0.3B$0.1B$0.0B$0.1B$0.1B$-0.0B$0.0B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$-0.2B$-0.1B$-0.1B$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B
Investing Cash Flow$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.6B$0.3B$0.2B$0.0B$0.0B$0.2B$0.1B$0.1B
← Companies